Skip to main content

Table 1 Baseline characteristics of included patients

From: NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner

Variables All patients (n = 245) Low NCSTN (n = 107) High NCSTN (n = 138) P value
Patient factors/Laboratory parameters
Age [year, mean (SD)] 51.6 (12.4) 51.5 (12.4) 51.8 (12.4) 0.825
Male gender, n (%) 201 (82.0) 83 (77.6) 118 (85.5) 0.132
HBsAg, [positive, n (%)] 210 (85.7) 95 (88.8) 115 (83.3) 0.228
AFP ≥ 400, n (%) 93 (38.0) 32 (29.9) 61 (44.2) 0.022
Ascites, n (%) 30 (12.2) 12 (11.2) 18 (13.0) 0.665
Histological and gross features of tumors
Tumor size, [cm, mean (SD)] 5.7 (3.3) 4.3 (3.2) 6.3 (3.3) < 0.001
Solitary tumor, n (%) 204 (83.3) 92 (86.0) 112 (81.1) 0.332
Tumor differentiation     0.027
Well/Moderate 143 (58.4) 69 (64.5) 74 (53.6)  
Poor 102 (41.6) 38 (35.5) 64 (49.5)  
Macrovascular invasion, n (%) 9 (3.7) 4 (3.7) 5 (3.6) 0.962
Microvascular invasion, n (%) 80 (32.7) 32 (29.9) 48 (34.8) 0.420
Cirrhosis, n (%) 153 (62.4) 66 (61.7) 87 (63.0) 0.827
TNM stage, n (%)     0.060
I- II 186 (75.9) 86 (80.4) 100 (72.5)  
III 59 (24.1) 21 (19.6) 38 (27.5)  
BCLC stage     0.493
A 198 (80.8) 83 (77.6) 115 (83.3))  
B 36 (14.7) 19 (17.8) 18 (13.0)  
C 10 (4.1) 5 (4.7) 5 (3.6)  
Prognostic outcome
Overall survival, months, mean (95% CI) 31.5 (29.5, 33.6) 36.0 (32.7, 39.3) 28.1 (25.6, 30.6)  
  1. TNM Tumor-node-metastasis, SD Standard deviation, CI Confidence interval